-
Not Synced
After we've been exposed to an infection
-
Not Synced
our immune system remembers the threat
-
Not Synced
in particular by producing antibodies
-
Not Synced
These are proteins that circulate in the
blood and throughout the body
-
Not Synced
They quickly recognize and disable the
invader upon contact
-
Not Synced
thereby preventing or minimizing illness
-
Not Synced
This is why we usually do not get sick
with the same bug twice
-
Not Synced
We are immune
-
Not Synced
Vaccines mimic this process
-
Not Synced
encouraging the immune system to make
antibodies
-
Not Synced
without us having to go through
the illness
-
Not Synced
Some of the leading SARS-CoV-2 vaccine
candidates are
-
Not Synced
mRNA vaccines
-
Not Synced
based on incorporating the
genetic blueprint
-
Not Synced
for the key spike protein on the virus surface
-
Not Synced
into a formula that, when injected into
humans,
-
Not Synced
instructs our own cells to make the spike
protein
-
Not Synced
In turn, the body then makes antibodies
against the spike protein
-
Not Synced
and they protect us against
viral infection
-
Not Synced
This strategy is faster than more
traditional approaches
-
Not Synced
Which often involve generating weakened or
inactivated forms of a live virus
-
Not Synced
or making large amounts of the spike
protein
-
Not Synced
to determine whether they can prompt
an antibody response
-
Not Synced
Once a potential vaccine is discovered,
-
Not Synced
a number of checkpoints exist before it
can be administered to people
-
Not Synced
First, a pre-clinical test, which involves
-
Not Synced
experiments in a laboratory and with
animals
-
Not Synced
Scientists must ensure the vaccine
candidate
-
Not Synced
is not only effective, but also safe
-
Not Synced
For example, an antibody response to an
imperfect vaccine could,
-
Not Synced
under extremely rare circumstances
-
Not Synced
end up increasing the danger of becoming
infected
-
Not Synced
When the potential vaccine achieves
the necessary pre-clinical results
-
Not Synced
clinical trials can begin in a small
group of people
-
Not Synced
As the vaccine candidate advances
-
Not Synced
it is tested on increasing numbers of
people
-
Not Synced
with scientists and doctors closely
monitoring
-
Not Synced
safety, efficacy, and dosing
-
Not Synced
Upon successful completion of
clinical trials,
-
Not Synced
the vaccine